Skip to main content



Lyon, October 19, 2021 – Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, today announces its cash flow as of September 30, 2021.

The total funds available at September 30, 2021 amounted to € 12.5 million against € 13.5 million as at June 30, 2021. The Company’s cash position is relatively stable and offers financial visibility over the next 18 months in accordance with the objectives fixed. During the second half of 2021, the Company should also benefit from the 2020 Research Tax Credit (CIR) for an amount of € 1.0 million, and from Bpifrance financing for an amount of € 1.0 million as part of the project. Neurolead.

Thierry Lambert, CFO of Theranexus, makes the following comment: “The Company’s cash position of € 12.5 million at September 30, 2021 illustrates controlled cash consumption and is in line with our objective of maintaining financial visibility for at least the next 18 months.

Theranexus appoints Marie Sebille as Chief Medical Officer

The Company has appointed Marie Sebille, MD, PhD, as Chief Medical Officer to lead the main clinical development programs of Theranexus. Dr Werner Rein will continue to support the Company as a senior consultant in its overall clinical development strategy.

Marie is a doctor of medicine by training and holds a doctorate in neuroscience. She has nearly 30 years of experience in the pharmaceutical industry, where she held various positions as a physician in global medical and clinical development. She contributed to the development of multiple drugs in neurology and psychiatry, then she held several management positions in charge of clinical operations within Sanofi’s R&D. During her tenure, Marie’s organization supported all major registration dossiers in the areas of rare diseases, oncology, I&I and diabetes and metabolism, as well as management programs. life cycle.

Franck Mouthon, Chairman and CEO and co-founder of Theranexus, made the following comments: “We are delighted to welcome Marie to support us in the pursuit of our clinical programs. His expertise in the development of drugs for neurology and rare diseases is a key asset for Theranexus. We also thank Werner for his contribution to the development of the Theranexus pipeline and we are pleased to continue to benefit from his strategic vision. “

Progress of the main clinical programs

THN 102 Drug Candidate – Excessive Daytime Sleepiness (EDS) in Parkinson’s Disease

THN102 is the first potential treatment for excessive daytime sleepiness (EDS) in patients with Parkinson’s disease. Discussions with several potential industrial partners are continuing. The teams remain fully committed and dedicated to ensuring the industrial development of the THN 102 drug candidate through an industrial partnership governing the format of use, the geographic areas concerned and the clinical development path.

BBDF 101 drug candidate for Batten disease, a rare orphan pediatric disease of the nervous system

Beginning of September 20211, Theranexus announced that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to initiate a Phase I / II clinical trial of its drug candidate BBDF 101 for juvenile Batten disease, a rare and fatal disease.

The clinical program will start at the end of 2021 with Phase I / II. Phase III will begin after consultation with the FDA in the second half of 2022, once pharmacokinetic and safety results have been established during the first 4.5 months of Phase I / II treatment.


Theranexus is a clinical stage biopharmaceutical company created by the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of diseases of the nervous system.

Thanks to its knowledge of neuronal and glial cell interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a strong and diverse portfolio of drug candidates in the clinical phase. The company’s combined drug reconversion strategy based on a solid commercial base and an ability to rapidly demonstrate clinical merit, enables it to produce various high value-added proprietary drug candidates, significantly reducing development time and costs. and dramatically increase the chances of its drugs hitting the market.

Thus, THERANEXUS is well positioned in several indications, including Parkinson’s disease and Batten disease, for which there is currently no treatment available.

Theranexus is listed on the Euronext Growth market in Paris (FR0013286259-ALTHX).

More information at:

  • See September 9, 2021 press release (Theranexus and Beyond Batten Disease Foundation (BBDF) Obtain American Investigational New Drug (IND) Approval to Start Clinical Development of BBDF 101)


More information on :

Click and follow us on Twitter and Linkedln



NEWS finance & communication



Financial director

Investor Relations

[email protected]

+33 (0) 1 53 67 36 79

[email protected]



Media relations



Theranexus SA published this content on October 19, 2021 and is solely responsible for the information it contains. Distributed by Public, unedited and unmodified, on October 19, 2021 08:10:15 PM UTC.

Leave a Reply